about
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's diseaseSources of variance in baseline gene expression in the rodent liverInfluence of Bisphenol A on Type 2 Diabetes MellitusPharmacogenomics and drug response in cardiovascular disordersFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesDoes the home environment and the sex of the child modify the adverse effects of prenatal exposure to chlorpyrifos on child working memory?Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analysesAtrial fibrillation in women: treatmentSteady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sexEffects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.Therapeutic drug monitoring in a developing nation: a clinical guide.Sex-specific gene expression in the BXD mouse liverMonitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular diseaseRenal function, bisphenol A, and alkylphenols: results from the National Health and Nutrition Examination Survey (NHANES 2003-2006)Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 yearsSex-dependent modulation of treatment responseGender differences, polypharmacy, and potential pharmacological interactions in the elderly.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patientsThe effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot studyPattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospitalCardiologic side effects of psychotropic drugs.Sex-and age-based differences in the delivery and outcomes of critical care.Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats.Gender-based personalized pharmacotherapy: a systematic review.Therapeutic implications of the gender-specific aspects of cardiovascular disease.Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Transcriptome analysis in peripheral blood of humans exposed to environmental carcinogens: a promising new biomarker in environmental health studies.Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.The circadian clock components CRY1 and CRY2 are necessary to sustain sex dimorphism in mouse liver metabolism.Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestionGender has a small but statistically significant effect on clearance of CYP3A substrate drugs.Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis.Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
P2860
Q24564761-79A490AE-EE3E-4A5B-A8CD-DDF6D5150099Q27024366-17A705E8-F4FA-4589-99C7-AC691304BBA8Q28075627-15019B47-1487-4346-9A98-5AFDD3DD9340Q28171051-1E95DA69-51B2-4210-841C-B0C8D7CFFE7EQ28182631-3E40B8F4-4CB5-403D-9160-CF21B862854EQ28394805-42820C8C-B37E-4AEB-A3C4-9C7B51841216Q28593306-3AFD821F-3188-4D4D-B0AF-E22DB0E44797Q30241862-086CC134-DDC4-400B-8863-E650A50DE45EQ33683890-00460B98-4ABD-405D-BCD3-4DC08631AB6BQ33722140-81C25DA4-E40B-434B-8DC2-1D7C3575FA60Q33908116-D7E1773E-242D-45E0-8908-D24DC220F37AQ34090751-A37E5187-2953-449E-8D88-0AC473FD7AECQ34706460-EDE5B355-AFB1-4A93-A32A-E22612407577Q34834681-A2F142F9-DB86-4625-9FDC-207A5B69C91AQ35127775-C82F6864-FC1B-44AB-B335-D1852F392E69Q35236761-D8A535B9-6E35-4A8B-A67D-3941C4828FEFQ35473198-2F69EEBF-0F84-4161-B4B5-F5E6FC70ABF0Q35619332-3C2B0369-3997-4AA5-94EC-DB9B79BF0DEDQ35805941-DCBFC7E9-1E14-4D88-AEDD-83398E5143D7Q35807339-E2DC6229-484E-4BA4-83D1-F357370FAFEEQ35826102-3DDA8D3D-4AFF-4920-BEFC-73C169ADCE7CQ35826765-CFB88C0F-2802-4744-8AC4-B3B70FB4F56CQ35827669-E3752FBD-4647-4568-8A7A-FB347AC859C7Q35906518-A703EEAC-BAA7-4DCD-B5EB-30AEB365EA75Q36077336-880C68F6-6FFF-4A7C-ADB1-2527B3EEE49EQ36173685-FB334D64-0A31-4919-88EA-7F238C85BC79Q36295326-CEC3DB74-E67D-40EA-BA34-BAB80E04D87CQ36335289-A93357C8-AA4F-47AB-A1C7-1D44B89B7087Q36467824-D24B00CF-8004-4554-AF71-FB66714C4810Q36544862-4BA5B69E-F0E0-48A9-B464-B68CB73C6019Q36603317-77F31987-9C23-4982-9C45-F99D9A040EBFQ36634909-3F327222-0120-4C10-BD30-A6B781C8AAC0Q36881692-00C30549-5EB1-4D98-8617-3DF8FFFD1C33Q36992238-9822C7DB-77A5-44BC-B2BD-05AD6FEE35DEQ37146495-C2B76845-5A94-4B81-B66C-02E31D00EC12Q37152824-49D38A9E-5460-48D4-BE33-9F96F7973F0AQ37233828-73E1D12A-1343-4FEA-ABBA-ECD5CFB164FBQ37256195-92C1A3F7-FDAD-4175-B991-7C370FDD27E0Q37265697-1B5CEA6D-79C8-40E0-91A3-D1B43E5B097CQ37538951-6498A30D-6D74-4F8E-82BE-FC1345DFF0DB
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The influence of sex on pharmacokinetics.
@ast
The influence of sex on pharmacokinetics.
@en
type
label
The influence of sex on pharmacokinetics.
@ast
The influence of sex on pharmacokinetics.
@en
prefLabel
The influence of sex on pharmacokinetics.
@ast
The influence of sex on pharmacokinetics.
@en
P1476
The influence of sex on pharmacokinetics.
@en
P2093
Janice B Schwartz
P2860
P304
P356
10.2165/00003088-200342020-00001
P577
2003-01-01T00:00:00Z
P6179
1026963827